Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00623727




Registration number
NCT00623727
Ethics application status
Date submitted
9/01/2008
Date registered
26/02/2008
Date last updated
15/07/2013

Titles & IDs
Public title
BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
Scientific title
Randomized, Active-controlled, Double-blind, Parallel Design Study to Evaluate the Efficacy and Safety of a Once-a-week Prophylaxis Treatment With BAY79-4980 Compared to Three Times-per-week Prophylaxis With rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
Secondary ID [1] 0 0
2007-003718-32
Secondary ID [2] 0 0
12781
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hemophilia A 0 0
Condition category
Condition code
Blood 0 0 0 0
Clotting disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - rFVIII-FS/pegylated liposomes (BAY79-4980)
Treatment: Other - rFVIII-FS/WFI (BAY14-2222)

Experimental: rFVIII-FS/pegylated liposomes (BAY79-4980) - 35 IU/kg body weight of BAY79-4980 1x/week plus 2 dummy injections/week (dummy = rFVIII (recombinant factor VIII)-FS (formulated with sucrose) excipient reconstituted in WFI (sterile water for injection))

Active comparator: rFVIII-FS/WFI (BAY14-2222) - 25 IU/kg body weight of rFVIII-FS 3x/week (employing 1 percent POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)-alone liposome (rFVIII-FS-POPC) as blinding agent used for first weekly injection and rFVIII-FS in WFI for 2nd and 3rd injection)


Treatment: Other: rFVIII-FS/pegylated liposomes (BAY79-4980)
35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm

Treatment: Other: rFVIII-FS/WFI (BAY14-2222)
25 IU/kg body weight intravenous 3x/week for 52 weeks
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Less Than 9 Total Bleeds Per Year
Timepoint [1] 0 0
up to one year
Secondary outcome [1] 0 0
Percentage of Participants With Less Than 5 Joint Bleeds Per Year
Timepoint [1] 0 0
up to one year
Secondary outcome [2] 0 0
Number of Joint Bleeds Per Participant Per Year in Responders
Timepoint [2] 0 0
up to one year

Eligibility
Key inclusion criteria
* Males aged 12 to 70 years
* Subjects with severe hemophilia A (< 1% factor VIII [FVIII]:C)
* Subjects with equal or greater than 150 exposure days (EDs) with any FVIII in total
* Subjects who have been on-demand treatment with a minimum of 1 relevant bleed per month or have been on secondary prophylaxis treatment with not more than a 3x/week schedule
* Subjects with bleeding events and/or treatments during the last 6 months prior to study entry which are documented in the subjects medical records
* Subjects with no measurable inhibitor activity
* Subjects with no history of FVIII inhibitor antibody formation
* Written informed consent by subject and parent / legal representative, if < 18 years
Minimum age
12 Years
Maximum age
70 Years
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
* Subjects who are receiving primary prophylaxis
* Subjects on prophylaxis with documented requirements of > 75 IU/kg/week
* Subjects with any other bleeding disease beside hemophilia A (i.e., von Willebrand disease)
* Subjects with abnormal renal function
* Subjects with elevated hepatic transaminases
* Subjects on treatment with immunomodulatory agents within the last 3 months prior to study entry or during the study
* Subjects with known hypersensitivity to the active substance, mouse or hamster protein, liposomes or polyethyleneglycol (PEG)
* Subjects who require any pre-medication for FVIII injections

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2010
Sample size
Target
Accrual to date
Final
143
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
- Perth
Recruitment postcode(s) [1] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Louisiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
Nevada
Country [9] 0 0
United States of America
State/province [9] 0 0
New Mexico
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Wisconsin
Country [16] 0 0
Argentina
State/province [16] 0 0
Ciudad Auton. de Buenos Aires
Country [17] 0 0
Argentina
State/province [17] 0 0
Santa Fe
Country [18] 0 0
Austria
State/province [18] 0 0
Graz
Country [19] 0 0
Austria
State/province [19] 0 0
Wien
Country [20] 0 0
Belgium
State/province [20] 0 0
Bruxelles - Brussel
Country [21] 0 0
Belgium
State/province [21] 0 0
Leuven
Country [22] 0 0
Canada
State/province [22] 0 0
Alberta
Country [23] 0 0
Canada
State/province [23] 0 0
Nova Scotia
Country [24] 0 0
Canada
State/province [24] 0 0
Ontario
Country [25] 0 0
Chile
State/province [25] 0 0
Santiago de Chile
Country [26] 0 0
Chile
State/province [26] 0 0
Santiago
Country [27] 0 0
Croatia
State/province [27] 0 0
Zagreb
Country [28] 0 0
Denmark
State/province [28] 0 0
Århus N
Country [29] 0 0
Estonia
State/province [29] 0 0
Tallinn
Country [30] 0 0
Estonia
State/province [30] 0 0
Tallin
Country [31] 0 0
France
State/province [31] 0 0
Besancon
Country [32] 0 0
France
State/province [32] 0 0
Le Kremlin-bicetre
Country [33] 0 0
France
State/province [33] 0 0
Lyon Cedex
Country [34] 0 0
France
State/province [34] 0 0
Marseille
Country [35] 0 0
France
State/province [35] 0 0
Montpellier Cedex
Country [36] 0 0
France
State/province [36] 0 0
Paris
Country [37] 0 0
France
State/province [37] 0 0
Rennes Cedex
Country [38] 0 0
France
State/province [38] 0 0
Strasbourg
Country [39] 0 0
Germany
State/province [39] 0 0
Nordrhein-Westfalen
Country [40] 0 0
Germany
State/province [40] 0 0
Berlin
Country [41] 0 0
Israel
State/province [41] 0 0
Tel Hashomer
Country [42] 0 0
Italy
State/province [42] 0 0
Catania
Country [43] 0 0
Italy
State/province [43] 0 0
Firenze
Country [44] 0 0
Italy
State/province [44] 0 0
Milano
Country [45] 0 0
Italy
State/province [45] 0 0
Napoli
Country [46] 0 0
Italy
State/province [46] 0 0
Torino
Country [47] 0 0
Lithuania
State/province [47] 0 0
Klaipeda
Country [48] 0 0
Lithuania
State/province [48] 0 0
Vilnius
Country [49] 0 0
Netherlands
State/province [49] 0 0
Groningen
Country [50] 0 0
Netherlands
State/province [50] 0 0
Nijmegen
Country [51] 0 0
Netherlands
State/province [51] 0 0
Utrecht
Country [52] 0 0
New Zealand
State/province [52] 0 0
Auckland
Country [53] 0 0
New Zealand
State/province [53] 0 0
Christchurch
Country [54] 0 0
Norway
State/province [54] 0 0
Oslo
Country [55] 0 0
Poland
State/province [55] 0 0
Gdansk
Country [56] 0 0
Poland
State/province [56] 0 0
Krakow
Country [57] 0 0
Poland
State/province [57] 0 0
Lodz
Country [58] 0 0
Poland
State/province [58] 0 0
Poznan
Country [59] 0 0
Poland
State/province [59] 0 0
Warszawa
Country [60] 0 0
Romania
State/province [60] 0 0
Timis
Country [61] 0 0
Romania
State/province [61] 0 0
Brasov
Country [62] 0 0
Romania
State/province [62] 0 0
Bucharest
Country [63] 0 0
South Africa
State/province [63] 0 0
Gauteng
Country [64] 0 0
Spain
State/province [64] 0 0
Andalucía
Country [65] 0 0
Spain
State/province [65] 0 0
Asturias
Country [66] 0 0
Spain
State/province [66] 0 0
Santa Cruz de Tenerife
Country [67] 0 0
Spain
State/province [67] 0 0
Barcelona
Country [68] 0 0
Spain
State/province [68] 0 0
Madrid
Country [69] 0 0
Spain
State/province [69] 0 0
Valencia
Country [70] 0 0
Switzerland
State/province [70] 0 0
Bern
Country [71] 0 0
Taiwan
State/province [71] 0 0
Changhua
Country [72] 0 0
Taiwan
State/province [72] 0 0
Taipei
Country [73] 0 0
Turkey
State/province [73] 0 0
Adana
Country [74] 0 0
Turkey
State/province [74] 0 0
Antalya
Country [75] 0 0
Turkey
State/province [75] 0 0
Izmir
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Cambridgeshire
Country [77] 0 0
United Kingdom
State/province [77] 0 0
South Glamorgan
Country [78] 0 0
United Kingdom
State/province [78] 0 0
South Yorkshire
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Birmingham
Country [80] 0 0
United Kingdom
State/province [80] 0 0
London
Country [81] 0 0
United Kingdom
State/province [81] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents


Results are available at https://clinicaltrials.gov/study/NCT00623727